Yuhanjang Pharmaceutical Ter... > 경제기사 | economics

Photo= Yonhap news

[Alpha Biz= Reporter Kim Sangjin] Yuhanjang Pharmaceutical has terminated its technology transfer agreement with global pharmaceutical company Gilead Sciences for a treatment related to metabolic-associated steatotic liver disease MASH, resulting in the return of rights associated with the therapy. This contract termination involves rights valued at approximately $785 million about 1 trillion Korean won.
In January 2019, Gilead secured exclusive rights to develop two drug candidates targeting metabolic-associated steatotic liver disease, excluding South Korea.

With the return of rights, Yuhanjang will not have to refund the upfront payment of $15 million around 20.2 billion Korean won already received. The company plans to explore options for new indications and potential partners for the MASH treatment moving forward.


관련기사

▶ Boeing Plans to Cut 17,000 Jobs, Affecting 10% of Workforce

▶ Foreign Investors Pull Out of Samsung Electronics as Market Value Plummets by 90 Trillion KRW

▶ Banking Sector Faces Criticism as Recovery Rate from Fraud Cases Stands at Only 9%

▶ Shinhan Investment Corp. Reports 130 Billion KRW Loss from ETF LP Operations

▶ Samsung Partners with Japans KDDI to Supply 5G Communication Equipment in 2025

/ 알파경제 Kim SangJin Reporter